ABO-incompatible (ABOi) dual-graft (DG) adult living donor liver transplantation (ALDLT) is not commonly performed due to its inherently intricate surgical technique and immunological complexity. Therefore, data are lacking on the short-and long-term clinical outcomes of ABOi DG ALDLT. We performed a retrospective study by reviewing the medical records of patients who underwent ABOi DG ALDLT between 2008 and 2014. Additionally, computed tomography volumetric analysis was conducted to assess the graft regeneration rate. The mean age of a total of 28 recipients was 50.2 ± 8.5 years, and the mean model for end-stage liver disease score was 12.2 ± 4.6.
| INTRODUCTION
Living donor liver transplantation (LDLT) is replacing the role of deceased donor liver transplantation (DDLT) in countries with extreme scarcity of deceased donor organs. In contrast to using a whole-sized graft as in DDLT, adult living donor liver transplantation (ALDLT) using partial liver grafts has an intrinsic risk of small-for-size graft (SFSG) syndrome, which is confronted with donor safety in terms of remnant liver volume and hepatic steatosis. Thus, donor safety and SFSG syndrome still remain as unresolved problems and have limited the broadening of the border in ALDLT. To overcome such obstacles in LDLT, Lee et al introduced dual-graft (DG) LDLT.
1,2 Since the first successful DG ALDLT in 2000, the feasibility of DG ALDLT has been shown in terms of survival outcome and expansion of the living donor (LD) pool.
In another aspect of LD pool expansion, ABO-incompatible (ABOi)
ALDLT has demonstrated patient and graft survival outcomes comparable to that of ABO-compatible (ABOc) ALDLT, which is attributable to the advancement of desensitization (DSZ) with anti-CD20 monoclonal antibody rituximab. Therefore, the threshold of ABO incompatibility as an obstacle for the expansion of the LD pool has been drastically lowered. [3] [4] [5] [6] In a previous report, we introduced an innovative surgical tactic-DG ALDLT with ABOi graft-to simultaneously overcome SFSG and the ABO blood group barrier. 7 We reported promising preliminary results from 3 cases of DG ALDLT with ABOi and ABOc grafts with a mean follow-up period of 9.5 months, suggesting its potential contribution to the expansion of LD pool. However, its clinical consequences and long-term outcomes, particularly of the ABOi graft, are still to be identified. Therefore, in the current study, we aimed to describe the short-and long-term outcomes of ABOi DG ALDLTs. Furthermore, we analyzed the outcome of the ABOi graft by comparing the regeneration rate between ABOi and ABOc grafts.
| MATERIALS AND METHODS

| Study population
Adult patients (≥18 years) who underwent ABOi DG LDLT between January 2008 and December 2014 at Asan Medical Center, Seoul, Korea, were retrospectively reviewed.
| Indication for DG ALDLT
The donor evaluation process and selection criteria were the same as in single-graft (SG) ALDLT, as described previously. 8 DG ALDLT with 2 left lobe (LL) grafts (from 2 donors who were not acceptable for right lobe [RL] donations) was considered when the estimated graftto-recipient body weight ratio (eGRWR) of each LL individual graft was <0.8 but the sum of the 2 LL grafts combined was at least 0.8. DG with a RL and LL combination was indicated when the eGRWR of the RL was <0.8 but satisfied 0.8 when combined with the LL graft. Once an eGRWR of 0.8 was met, the left lateral section (LLS) was preferred to an LL graft. A more detailed indication for DG ALDLT and the graft selection criteria has been described in detail previously. 
| Desensitization protocol and immunosuppression
All recipients in this study received the same DSZ protocol and immunosuppressant regimen as in ABOi SG ALDLT. All patients were administered a single dose of rituximab (300-375 mg/m 2 per body surface area) at 2-3 weeks prior to liver transplantation (LT), which was followed by total plasma exchange (TPE) 1 week later. The TPE schedule was modified according to the initial isoagglutinin (IA) titer of the recipient and continued before LT until the target IA titer of 1:8 or less was acquired.
The immunosuppression protocol consisted primarily of IL-2 receptor antagonist (basiliximab) induction and intraoperative administration of methylprednisolone (dosage of 10 mg/kg) at the anhepatic phase, followed by a triple postoperative regimen of tacrolimus, mycophenolate mofetil, and methylprednisolone. The initial target trough level of tacrolimus was approximately 8 to 10 ng/dL. The dosage of mycophenolate mofetil (500 to 1500 mg/d) was adjusted depending on the body weight of the recipient. Methylprednisolone was usually tapered off over 3 months after LT. 
| Monitoring for AMR/Diagnosis and management of AMR
| Surgical procedure and graft selection for location
The operations on the recipient and 2 donors were started simul- 
| Anticoagulation after DG ALDLT with ABOi graft
Prostaglandin E1 was started immediately after the reperfusion of the graft and injected continuously during first 3 weeks for ABOi recipients, which was a week longer than ABOc ALDLT patients. As was the case for all ABOc ALDLT recipients, DG ALDLT patients with ABOi grafts were also administered low dose aspirin (100 mg/d) until 3 months after the LT.
| Assessment for graft regeneration
To evaluate the difference in the graft regeneration rates between was then computed through CT volumetry. In this study, the "regeneration rate (%)" of the graft was defined using the following formula:
regeneration rate (%) = [GV by CT volumetry (mL) -GV by previous CT volumetry (mL)]/GV by previous CT volumetry (mL) × 100. A P value of <.05 was considered to indicate significant difference.
| Statistical analysis
| Ethical considerations
As in SG ALDLT, the living liver donation process for every case of DG ALDLT was inquired and approbated by the Korean Network for 
| RESULTS
From
| Demographic data of recipients
The mean age of the recipients was 50.2 ± 8.5 years (range: 30-68 years), and 23 patients (82.1%) were men. The mean model for end-stage liver disease (MELD) score was 12.2 ± 4.6 (range: 6-23).
The most common original disease was hepatitis B virus-associated liver cirrhosis (82.1% of patients), and 17 patients (60.7%) had hepatocellular carcinoma.
When we compared the demographic data between the 28 cases of ABOi and the 145 cases of ABOc DG ALDLT, the mean MELD score of the ABOi DG ALDLT patients was significantly lower than that of the ABOc DG ALDLT patients (Table 1) . No intensive care unit-bound patients requiring a life support device or vasopressor were indicated for ABOi DG ALDLT.
In comparing the immunological characteristics particularly relevant to ABO incompatibility, such as IA titer, CD20-positive B lymphocyte, and frequency of TPE, we found no significant differences between the ABOc + ABOi group and the ABOi + ABOi group (Table 2) .
| Donors, grafts, and operation profile
The first case of ABOi DG ALDLT was originally performed by combining an ABOi graft from a LD and an ABOc graft from a A combination of right liver and left liver grafts was used in 9 cases, and a combination of 2 left liver grafts was used in the remaining 19
cases. The most commonly used graft type was LL (n = 39, 69.6%). The mean graft-to-recipient weight ratio (GRWR) was 1.07% (range: 0.69-1.42%). No significant differences in terms of donor, graft, and operation factors were observed between the ABOi and ABOc DG ALDLT groups except the amount of intraoperative red blood cell transfusion (Table 1 ).
| Survival outcomes
During the mean follow-up period of 57.0 ± 22.4 months, only 1 patient died, which was an in-hospital mortality due to pneumonia that occurred on the 27th day after LDLT. The 1-, 3-, and 5-year patient survival rates were all 96.4%. The patient survival rate was not significantly different between ABOi DG ALDLT and ABOc DG ALDLT (P = .112, Figure 2 ).
In 2 patients, complete atrophy and disappearance of the unilateral graft occurred. The 1-, 3-, and 5-year survival rates of the 56 grafts in 28 patients were 96.4%, 94.2%, and 92.0%, respectively. The graft survival rate was not statistically different between ABOi DG ALDLT and ABOi SG ALDLT (P = .069, Figure 3 ).
T A B L E 1 Demographics of recipients and donors, and graft and operative profiles of DG ALDLT: ABOi (n = 28) compared to ABOc (n = 145) DG ALDLT T A B L E 1 (Continued)
| Morbidity
| Surgical complication
Twelve episodes of surgical complications occurred in 8 patients (28.6%). The most common complication was biliary strictures (BS), which occurred in 6 patients (21.4%) and 7 grafts (12.5%). Details of the surgical complications are presented in Table 3 . We performed percutaneous transhepatic portography with PV stent insertion for PV stenosis. HV outflow obstructions were managed through transjugular venography with HV stenting.
| Immunological complication
For pretransplant DSZ, a mean of 3.8 ± 1.7 TPE episodes were performed. During 1 month after LDLT, 6 patients required 7.0 ± 6.1 episodes of TPE (range: 2-19 times) due to a rebound rise of IA titer of 1:64 or more. A mean of 1.5 ± 3.9 TPE episodes were performed during the posttransplant period. There were no cases of AMR. Biopsyproven acute cellular rejection occurred only in 1 patient (3.6%)
bilaterally. Chronic rejection was not observed.
| Infectious complication
As demonstrated in Table 3 , incidences of infections in ABOi DG ALDLT recipients, including bacterial, fungal, and viral diseases, were not statistically different from those of ABOc DG ALDLT. grafts (P = .145, Figure 4A ).
| Graft regeneration
The mean values of preoperative estimated GV of each ABOi and ABOc graft were 343.7 ± 128.6 mL and 360.2 ± 116.8 mL, respectively. When we compared 1-month, 6-month, and 1-year graft regeneration rates of ABOi and ABOc grafts, there were no significant differences (Table 4) . Similarly, the transition of total graft volume in ABOc + ABOi and ABOi + ABOi groups showed no significant differences either (Table 5 ). As detailed in Tables 6 and 7 , no statistically significant differences were observed in graft regeneration rates based on graft location (RSG vs LSG) or presence with ABOi grafts.
In 2 patients who received ABOc and ABOi graft combination, complete unilateral graft atrophy without antecedent technical issues, such as PV stenosis, BS, or obstruction of HV outflow and immunological complications including AMR or ACR, the so-called "vanishing graft phenomena" occurred. The 2 atrophied grafts were both ABOi and orthotopically positioned LSGs. Significant atrophy (>50% of GV checked on first week after LDLT) was found at 4 and 8 months, respectively, and eventually disappeared at 3 and 4 years after LDLT ( Figures 5A and 5B) . However, both cases were asymptomatic and their LFTs were unaffected.
| Biliary complication
The incidence of BS in ABOi grafts was 7.9%, which was not significantly different from 22.2% in ABOc grafts (P = .195). The comparison of BS-free survival between ABOi and ABOc grafts showed comparable outcomes (P = .133, Figure 4B ). The 1-and 3-year BS-free graft survival rates were 83.3% and 77.8% in ABOc grafts, respectively, and 94.4% and 91.7% in ABOi grafts, respectively. There were no radiologic signs of AMR or diffuse intrahepatic biliary stricture (DIHBS) in the 38 ABOi grafts. In the univariate and multivariate analysis for BS, ABO incompatibility was not a significant risk factor for BS. BD anastomosis performed as HJ was an independent significant risk factor in univariate analysis, but was not statistically significant in multivariate analysis (Table 8 ).
| Donor outcome
There were no morbidities or mortalities among the 55 LDs, including wound infection, bile leakage, BS, bleeding, or other surgical and even medical complications. All LDs recovered well without any complications and were discharged after a mean of 12.5 ± 3.4 days following operation. No LDs were readmitted after discharge. The follow-up CT scans performed 1 year after donor hepatectomy and laboratory tests including LFTs showed no unusual findings. This discrepancy is the driving force for the development of LDLT in Asian countries, including Korea.
T A B L E 3 Comparison of complications (Clavien-Dindo Classification III) between ABOi and ABOc DG ALDLT
Despite recent technical innovations, improvement of perioperative care, and enhanced understanding of hemodynamics, SFSG syndrome still remains an unresolved problem afflicting ALDLT. Therefore, sufficient GV is one of the crucial prerequisites for successful ALDLT. Most programs currently accept the arbitrary requirement of an estimated GV >0.8%-1.0% of eGRWR, or 40%-50% of GV to standard liver volume (SLV) ratio. [11] [12] [13] [14] As such, LL graft cannot be accepted for most ALDLTs owing to SFSG issues. However, for safe donor hepatectomy, live donation of right liver is permissible only if the remnant liver volume exceeds 30%-35% of the total liver volume and hepatic steatosis is <15%-35%. [15] [16] [17] [18] [19] As a result, >60% to 70% of LD candidates cannot be accepted for right liver donation due to liver volume and hepatic steatosis issues. DG ALDLT may therefore be an answer to the dilemma between donor safety and recipient outcome. In the present study, all LDs were rejected because of low eGRWR with LL graft (even RL graft in 9 patients) and insufficient estimated remnant liver volume after RL procurement.
Guaranteeing sufficient GV for an acceptable outcome with 2 suboptimal grafts without taking an excessive risk in a marginal donor is the greatest advantage of DG ALDLT. It is a technically complicated procedure that has a notably longer operation time and increased incidence of surgical complications. 9 However, considering the domestic situation of an organ shortage from deceased donors, ALDLT is the one of the few viable options to save a life. Because of the risks associated with donor hepatectomy, the involvement of 2 LDs may be accepted and justified only if favorable survival outcomes of recipients are ascertained. The 1-, 3-, and 5-year patient survival rates of ABOi DG ALDLT were all 96.4%, which was comparable to that of ABOc DG ALDLT. Concurrently, all 55 LDs from our study recovered well without perioperative morbidities and were discharged at a mean of 12.5 days after donor hepatectomy. Donor outcomes in this study yielded acceptable results compared to that of ABOi SG ALDLT with the donor morbidity rate of 2.7% (P = .482). This is consistent with our previous report on donor morbidity of DG ALDLT (1.9%), which was comparable to that of SG ALDLT (2.2%, P = .467).
9
In addition to the issue of donor safety, the ABO blood group bar- ABOi grafts were placed orthotopically. Due to the small sample size, we could not find significant statistical correlation of graft location or ABO incompatibility with graft regeneration.
Liver regeneration after LT, especially in ALDLT, is crucial for meeting the metabolic demand of the recipient. Although still unclear, factors affecting graft regeneration after LT are reported to be ischemic injury, graft size, immunosuppression, steatosis, donor age, and viral hepatitis. 24 Conversely, Olthoff et al identified graft size, GV/SLV ratio, and body weight as the main predictors for liver regeneration after LDLT. 25 Also, spleen size, portal flow to the graft, GRWR, and patent hepatic outflow were positively correlated with graft regeneration after right lobe ALDLT. 26 There have been several studies on graft regeneration after LT; however, the effect of ABO incompatibility on graft regeneration is not well known. Also, graft regeneration in DG ALDLT is rarely reported because DG ALDLT is not widely performed. [20] [21] [22] [23] 26 Lu et al mentioned a portal flow and bilateral graft volume size discrepancy as potential factors associated with graft regeneration in DG ALDLT. 22 However, in contrast with this report, 4 of 9 atrophied grafts in our study showed no discrepancy between the initial graft volumes and the countergrafts, and even the larger grafts atrophied. Further studies and more cases are needed to define the factors associated with graft atrophy in DG ALDLT.
Due to its technically demanding nature, only a limited number of centers perform DG ALDLT. As a high-volume liver transplantation center, our institution has had the opportunity to gain experience with such unusual cases as ABOi DG ALDLT. The present study is the largest study to date on DG ALDLT using ABOi grafts. Our initial successful short-term outcome in ABOi DG ALDLT encouraged us to perform further operations with ABOc + ABOi grafts, and even both ABOi grafts, as components of DG ALDLT. As a result, 28 recipients of ABOi DG ALDLT were followed up for at least 2 years, ranging from 26 months up to 97 months of survival periods, showing acceptable and feasible outcomes. Because none of our recipients had DIHBS, we can say that there was no additional risk associated with ABO incompatibility in our current study of ABOi DG ALDLT.
To conclude, in spite of its technical complexity, DG ALDLT consisting of ABOc + ABOi and ABOi + ABOi grafts is safe and effective, with acceptable survival outcome. Combining DG with ABOi ALDLT can be a feasible option for expanding the ALDLT donor pool without additional donor risks.
